



OVERSEAS MARKETS: GPI SIGNS CONTRACTS WORTH 16.6 MILLION Q4 2024 DRIVEN BY BLOOD AND AUTOMATION

Trento, 29 January 2025

For Gpi, the fourth quarter of 2024 marks a period of accelerated growth across international markets. The Group's offerings remain distinguished on an international scale: in the last quarter of 2024, the value of contracts secured abroad amounted to € 16.6 million, marking a 26% rise from the same quarter the previous year.

Software remains the main catalyst for foreign operations, with contracts signed amounting to nearly € 12 million. Notably, Gpi4Med.BLOOD, the suite specialised in managing the blood supply chain (including software for donations, transfusions, and additional applications), excels thanks to the remarkable performance across all its vertical product lines. France and the United States remain pivotal markets for these solutions, securing the most lucrative contracts. Gpi France's accomplishments are particularly impressive, having secured contracts worth € 3.5 million. This success highlights the effectiveness of its commercial ventures in French-speaking areas and also the Middle East, where deals valued at approximately € 2 million were clinched in Saudi Arabia. The other components of the Gpi4Med Suite - a range of software and medical devices for the diagnosis and treatment of patients - successfully achieved the expected revenue outcomes, in line with previous reporting periods, and exhibited a strong foothold especially in Europe.

Riedl, the **pharmacy automation robot**, experienced substantial growth, leading to new contracts amounting to € **4.5 million**, more than doubling the previous quarter's figure of € **2.1** million. Fuelling this expansion is Gpi CEE, capitalising on its broad sales network to bolster its footprint in significant regions like Austria, Germany, Hungary, Iceland, Poland, Slovenia, and Switzerland. An important milestone is Riedl's first installation in Northern Ireland, showcasing Gpi Britannia's prowess in successfully penetrating the UK market.

The Q4 2024 results confirm Gpi's growth on the international stage, driven by an **industrial approach that ensures the scalability and export of its solutions.** The Group bolsters its presence in key markets by leveraging its cutting-edge and internationally renowned proprietary technologies.



GPI GROUP

Gpi's mission is to make the healthcare systems sustainable through their digitisation, so that everyone can receive high-quality care. **Sustainability and social impact** are the guiding principles and play a crucial role in the strategic and investment assessments of the Group, aware that the solutions and services provided to the community have an impact on the quality of life of individuals.

For 35 years, driven by a patient-centric vision, Gpi has been working to support healthcare systems by providing the skills and innovative tools necessary to improve prevention and treatment processes. This is achieved through the strategic use of advanced software, technologies, and cutting-edge services.

The Group's strategy is designed to meet the evolving requirements of the constantly changing healthcare sector and to facilitate entry into international markets.

The unwavering commitment of its 7,600 employees and a customer base of more than 9,000 across 70 countries, yielded €433 million in revenue, an EBITDA of €80 million in 2023.

Gpi S.p.A. is listed on the Euronext Tech Leaders segment of Borsa Italiana, the Italian stock exchange.

ISIN ordinary shares: IT0005221517

This press release is also available at www.gpigroup.com and www.linfo.it

CONTACTS

Investor Relations

GPI | Fabrizio Redavid, Lorenzo Giollo | investor.relations@gpi.it | T: +390461381515 | Via Ragazzi del '99, 13 - 38123 Trento

Media Relations

GPI | Daniela Filbier, Enrico Orfano | media.relations@gpi.it | T: +390461381515 | Via Ragazzi del '99, 13 - 38123 Trento

Specialist

Banca Akros | Bruno Mestice | bruno.mestice@bancaakros.it | T. +3902434441 | Viale Eginardo, 29 – 20149 Milan



